America's antitrust regulators are taking aim at a deal that would reshape the business of supplying the nation's veterinary clinics.
The Federal Trade Commission, joined by attorneys general from 13 states, sued on Friday, November 13, to block Covetrus's proposed $3.5 billion acquisition of MWI Animal Health, according to dvm360, a veterinary industry publication. The FTC said the deal would combine the two largest veterinary distributors in the United States.
The complaint was filed in the US District Court for the Southern District of New York. It names Covetrus and its owners, the private equity firms Clayton, Dubilier & Rice and TPG. The commission voted 2-0 to authorise the lawsuit.
The deal
The transaction was announced in February 2026. Cencora, the pharmaceutical distribution giant formerly known as AmerisourceBergen, agreed to sell MWI Animal Health to Covetrus. Under the terms, Cencora would receive $1.25 billion in upfront cash, $800 million in preferred equity and $1.45 billion in common equity, and would keep a 34.3% non-controlling stake in the combined company, according to dvm360.
The FTC's concerns
The FTC argues that Covetrus and MWI compete closely in distributing products to veterinary clinics and to large corporate veterinary groups, and that combining them would reduce competition and raise prices, according to dvm360. Veterinary distributors supply clinics with medicines, vaccines, medical supplies, equipment and pet food.
The agency's press release did not include market share figures. In merger challenges, the FTC typically argues that a deal would give the combined company enough market power to raise prices, reduce service quality or limit innovation.
Covetrus fights back
Covetrus said it was prepared to defend the deal in court, according to dvm360. The company called the FTC's view of the market "narrow and outdated," arguing that veterinary clinics have many purchasing options, including buying directly from manufacturers, using other distributors and ordering through online marketplaces.
The outcome will depend on how the court defines the relevant market. If the market is defined broadly to include direct purchases and online channels, the combined company's share would be smaller. If it is defined narrowly to include only full-line veterinary distributors, the deal would look more concentrated.
Why veterinary distribution matters
The US pet care market has grown rapidly, driven by rising pet ownership and spending on pet health. Veterinary clinics have consolidated, with private equity firms and large corporate groups buying independent practices. Distributors play a central role in this ecosystem, supplying products and services that clinics depend on.
Rising costs of veterinary care have become a concern for pet owners, and regulators have scrutinised consolidation across the veterinary industry, including clinics, pharmacies and distributors.
Private equity under scrutiny
The case is also part of increased antitrust scrutiny of private equity deals in healthcare. Regulators have expressed concern that private equity firms are consolidating fragmented industries, from physician practices to veterinary clinics, in ways that raise prices for consumers. Covetrus was taken private by Clayton, Dubilier & Rice and TPG in 2022.

Cencora's strategy
For Cencora, the sale of MWI was part of a strategy to focus on its core business of distributing pharmaceuticals to pharmacies, hospitals and clinics. A blocked deal would force it to keep MWI or seek another buyer.



